 Targacept Inc. said it would abandon further development of TC-5214 as a treatment for overactive bladder after seeing disappointing results in a midstage study.. "The results were not compelling enough to justify the compound's continued development in overactive bladder," said Dr. Stephen A. Hill, the company's president and chief executive officer. . Shares...
  